Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.42 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.33 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4953782 | 1.00 | SLC7A5 (0.42) | SLC7A5SLC1A3SLC1A2SLC1A1USP2 | |
| SCHEMBL7689414 | 0.76 | SLC7A5 (0.43) | SLC7A5SLC1A3SLC1A2SLC1A1USP2 | |
| SCHEMBL29957453 | 0.69 | SLC7A5 (0.62) | SLC7A5SLC1A3SLC1A2SLC1A1USP2 | |
| SCHEMBL25933046 | 0.69 | SLC7A5 (0.62) | SLC7A5SLC1A3SLC1A2SLC1A1USP2 | |
| SCHEMBL468084 | 0.69 | SLC7A5 (0.62) | SLC7A5SLC1A3SLC1A2SLC1A1USP2 | |
| SCHEMBL1007447 | 0.69 | SLC7A5 (0.62) | SLC7A5SLC1A3SLC1A2SLC1A1USP2 | |
| SCHEMBL600021 | 0.69 | SLC7A5 (0.62) | SLC7A5SLC1A3SLC1A2SLC1A1USP2 | |
| SCHEMBL6510366 | 0.69 | — | — | |
| SCHEMBL6429649 | 0.67 | SLC7A5 (0.40) | SLC7A5SLC1A3SLC1A2SLC1A1USP2 | |
| SCHEMBL30011106 | 0.67 | SLC7A5 (0.40) | SLC7A5SLC1A3SLC1A2SLC1A1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442788-B2 | Antisense molecules and method of controlling expression of gene function by using the same | JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) | 2008-10-28 | — | — | US | claimed |
| US-6872809-B2 | Nucleoside derivatives | JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) | 2005-03-29 | — | — | US | claimed |
| US-20030208050-A1 | Nucleoside derivatives | JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) | 2003-11-06 | — | — | US | claimed |
| US-20030162739-A1 | Antisense molecules and method of controlling expression of gene function by using the same | JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) | 2003-08-28 | — | — | US | claimed |
| EP-1295892-A1 | ANTISENSE MOLECULES AND METHOD OF CONTROLLING EXPRESSION OF GENE FUNCTION BY USING THE SAME | Japan Science and Technology Corporation (JP) | 2003-03-26 | — | — | EP | claimed |
| EP-1295891-A1 | NUCLEOSIDE DERIVATIVES | Japan Science and Technology Corporation (JP) | 2003-03-26 | — | — | EP | claimed |
| US-7442788-B2 | Antisense molecules and method of controlling expression of gene function by using the same | JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) | 2008-10-28 | — | — | US | disclosed |
| US-6872809-B2 | Nucleoside derivatives | JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) | 2005-03-29 | — | — | US | disclosed |
| US-6872809-B2 | Nucleoside derivatives | JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) | 2005-03-29 | — | — | US | disclosed |
| EP-1295891-A4 | NUCLEOSIDE DERIVATIVES | JAPAN SCIENCE & TECH CORP (JP) | 2004-05-26 | — | — | EP | disclosed |
| US-20030208050-A1 | Nucleoside derivatives | JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) | 2003-11-06 | — | — | US | disclosed |
| US-20030208050-A1 | Nucleoside derivatives | JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) | 2003-11-06 | — | — | US | disclosed |
| US-20030162739-A1 | Antisense molecules and method of controlling expression of gene function by using the same | JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) | 2003-08-28 | — | — | US | disclosed |
| EP-1295892-A1 | ANTISENSE MOLECULES AND METHOD OF CONTROLLING EXPRESSION OF GENE FUNCTION BY USING THE SAME | Japan Science and Technology Corporation (JP) | 2003-03-26 | — | — | EP | disclosed |
| EP-1295891-A1 | NUCLEOSIDE DERIVATIVES | Japan Science and Technology Corporation (JP) | 2003-03-26 | — | — | EP | disclosed |
| EP-1295891-A1 | NUCLEOSIDE DERIVATIVES | Japan Science and Technology Corporation (JP) | 2003-03-26 | — | — | EP | disclosed |
| WO-2001096355-A1 | NUCLEOSIDE DERIVATIVES | JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162739-A1 | Antisense molecules and method of controlling expression of gene function by using the same | RNGTT, RNMT, UPF1 | SLC7A5 1628/4885SLC1A3 891/4885SLC1A2 720/4885 |
| US-20030208050-A1 | Nucleoside derivatives | RIMKLA, MTHFD1, AADAT | SLC7A5 72/4885SLC1A3 70/4885SLC1A2 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.